SALZBURG, Austria–(BUSINESS WIRE)–#dminepump—Launched as the D-mine® Pump, this
portable micro infusion device recently received European CE approval
and is currently being launched in several European countries. It was
specifically designed to provide precise continuous subcutaneous drug
delivery for Parkinson´s patients in a compact, simple to use and
patient friendly package.
EVER Pharma, a specialist in neurological diseases, now offers a
complete therapy package for Parkinson’s disease with D-mine®
Pump, D-mine® Pen and Dacepton®
(Dopaceptin®, Apomorphine hydrochloride).
Parkinson´s patients often have difficulty coordinating movement. So,
the ease of handling, safety and intuitive use were the primary goals
for the D-mine® Pump development. Leveraging special
micro-rotary pump technology, minimal buttons and a bespoke menu screen
interface, the device is conveniently compact and easy to use. It also
features automatic drug filling, multiple languages, data storage, and
does not require complex flow rate calculations.
“CE approval of the D-mine® Pump and the launch, is an
important milestone for our product portfolio in Parkinson´s disease.
EVER Pharma is now able to deliver an enhanced and comprehensive package
of care with its Parkinson´s disease medication Apomorphine and its own
Medical Devices”, explains Dominic Benning, Head of Dopaminergic Therapy
at EVER Pharma GmbH.
“With the development of the EVER Pharma D-mine® Pump
for Parkinson’s therapy, we have realized a very ambitious project with
challenging requirements. This considerable investment in this product
is a clear statement of the spirit of EVER Pharma to put focus on
patients’ needs and support with customized solutions. EVER Pharma
delivers a complete package with its Parkinson´s disease portfolio, from
medication to means of administration with innovative Medical Devices”,
explains Georges Kahwati, General Manager at EVER Pharma GmbH.
More information can be found at www.d-minecare.com.
About EVER Pharma GmbH
EVER Pharma is a fully integrated specialty pharmaceuticals company
focused on the research, development, production and commercialization
of products in the areas of neurology, critical care, anesthesia and
oncology.
From global headquarters in Austria it runs a dynamic operation
providing innovative therapies and value-added formulations aimed at
enhancing patient and healthcare professional’s lives through improved
safety and convenience.
The products are developed and manufactured at EU GMP certified
facilities in Austria and Germany. These are highly specialized in the
production of complex injectables including high potency substances,
crystal suspensions in vials, pre-filled syringes, ampoules and
implants. EVER markets its products in more than 70 countries around the
world through 25 international affiliated companies and strategic
partners.
Contacts
Contact Press
Marie-Kristin Schöppl
International
Marketing Manager
Phone: +43 7665 20555 530
E-Mail: [email protected]
www.everpharma.com
www.d-minecare.com
Contact Partner/Investor Relations
Dominic
Benning
Head of Dopaminergic Therapy
Phone: +43 7665 20555 861
E-Mail:
[email protected]
